-
Views
-
Cite
Cite
Tetsushi Yoshikawa, Yoshizo Asano, Masaru Ihira, Kyoko Suzuki, Masahiro Ohashi, Sadao Suga, Kazuko Kudo, Keizo Horibe, Seiji Kojima, Koji Kato, Takaharu Matsuyama, Yukihiro Nishiyama, Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk Factors, The Journal of Infectious Diseases, Volume 185, Issue 7, 1 April 2002, Pages 847–853, https://doi.org/10.1086/339411
- Share Icon Share
Abstract
Human herpesvirus 6 (HHV-6) infection was studied in 82 bone marrow transplant (BMT) recipients (72 allogeneic, 10 autologous). All recipients and 30 donors were seropositive for HHV-6 antibody at the time of bone marrow transplantation. Thirty-one recipients (37.8%) had HHV-6 viremia 2–4 weeks after transplantation. The incidence of HHV-6 viremia was significantly higher among allogeneic BMT recipients than in autologous BMT recipients (P = .011). Therefore, the following analyses of allogeneic BMT recipients were carried out (n = 72). Geometric mean antibody titers (log10) were significantly higher in recipients without viremia than in those with viremia (1.84 ± 0.39 vs. 1.61 ± 0.42; P = .022). Logistic regression analysis demonstrated that leukemia or lymphoma is an independent risk factor (P = .031) for HHV-6 viremia. Rash occurring within 1 month after transplantation was observed in 17 (54.8%) of 31 recipients with HHV-6 viremia but in only 8 (19.5%) of 41 recipients without HHV-6 viremia (P = .001).